Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,000 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y, Kato T, Kobayashi K, Daizumoto K, Fukuhara H, Ohira S, Katayama S, Shimizu R, Takamoto A, Nishimura K, Ikeda K, Nagami T, Hayashida Y, Hirama H, Naito H, Tomida R, Sasaki Y, Yamamoto S, Shimizu S, Sugimoto M; Chu-shikoku Japan Urological Consortium. Tohi Y, et al. Among authors: shimizu s, shimizu r. Jpn J Clin Oncol. 2024 Feb 7;54(2):167-174. doi: 10.1093/jjco/hyad143. Jpn J Clin Oncol. 2024. PMID: 37840362
Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y, Kato T, Fukuhara H, Kobayashi K, Ohira S, Ikeda K, Daizumoto K, Katayama S, Shimizu R, Nishimura K, Nagami T, Hayashida Y, Hirama H, Takamoto A, Dainichi T, Sugimoto M; Chu-shikoku Japan Urological Consortium. Tohi Y, et al. Among authors: shimizu r. Int J Clin Oncol. 2022 Aug;27(8):1348-1355. doi: 10.1007/s10147-022-02183-z. Epub 2022 May 20. Int J Clin Oncol. 2022. PMID: 35596089
Extent of pelvic lymph node dissection improves early oncological outcomes for patients with high-risk prostate cancer without lymph node involvement after robot-assisted radical prostatectomy.
Morizane S, Honda M, Shimizu R, Tsounapi P, Teraoka S, Yumioka T, Yamaguchi N, Kawamoto B, Iwamoto H, Hikita K, Takenaka A. Morizane S, et al. Among authors: shimizu r. Int J Clin Oncol. 2022 Apr;27(4):781-789. doi: 10.1007/s10147-022-02121-z. Epub 2022 Jan 25. Int J Clin Oncol. 2022. PMID: 35076818
C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy: A Japan Urological Oncology Group study analysis.
Nishikawa R, Miyake M, Morizane S, Shimizu R, Teraoka S, Honda M, Iida K, Nishimura N, Sazuka T, Kimura T, Ito A, Shiga K, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Takenaka A. Nishikawa R, et al. Among authors: shimizu r. Int J Urol. 2023 Mar;30(3):299-307. doi: 10.1111/iju.15106. Epub 2022 Nov 30. Int J Urol. 2023. PMID: 36448522
1,000 results